Summary of Bill HR 1794
Bill 119 hr 1794, also known as the Abraham Accords Office Act, aims to amend the Federal Food, Drug, and Cosmetic Act to create a new office within the Food and Drug Administration (FDA) called the Abraham Accords Office. This office would be responsible for overseeing and coordinating the FDA's efforts related to the Abraham Accords, a series of agreements between Israel and several Arab countries aimed at promoting peace and cooperation in the Middle East.
The bill outlines the duties of the Abraham Accords Office, which include facilitating the exchange of information and expertise between the FDA and its counterparts in the countries involved in the Abraham Accords. The office would also be tasked with promoting collaboration on regulatory issues related to food, drugs, and cosmetics, as well as identifying opportunities for joint research and development projects.
In addition to establishing the Abraham Accords Office, the bill also includes provisions for reporting requirements and oversight mechanisms to ensure that the office is effectively carrying out its duties. The overall goal of the legislation is to strengthen ties between the FDA and the countries involved in the Abraham Accords, ultimately leading to improved regulatory cooperation and increased opportunities for collaboration in the field of food, drugs, and cosmetics.
Overall, Bill 119 hr 1794 seeks to promote peace and cooperation in the Middle East through enhanced regulatory cooperation in the realm of food, drugs, and cosmetics. By establishing the Abraham Accords Office within the FDA, the bill aims to facilitate greater collaboration and information sharing between the United States and its partners in the region, ultimately benefiting consumers and promoting public health.